Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma — Stella

Home/Relapsed/ Refractory Multiple Myeloma/A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Relapsed/ Refractory Multiple Myeloma trials

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Tongji Hospital, Tongji Medical College, Wuhan, Hubei

Key details

Phase

Very early testing

Sponsor

Chunrui Li

Collaborators

Shenzhen Pregene Biopharma Co., Ltd.

Enrollment target

~24 participants

Started

January 2025

Primary completion

November 2027

Age range

18 Years and older

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.